GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qyuns Therapeutics Co Ltd (HKSE:02509) » Definitions » Total Stockholders Equity

Qyuns Therapeutics Co (HKSE:02509) Total Stockholders Equity : HK$244.5 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Qyuns Therapeutics Co Total Stockholders Equity?

Qyuns Therapeutics Co's Total Stockholders Equity for the quarter that ended in Dec. 2024 was HK$244.5 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Qyuns Therapeutics Co's Book Value per Share for the quarter that ended in Dec. 2024 was HK$1.10. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Qyuns Therapeutics Co's Debt-to-Equity for the quarter that ended in Dec. 2024 was 2.30.


Qyuns Therapeutics Co Total Stockholders Equity Historical Data

The historical data trend for Qyuns Therapeutics Co's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qyuns Therapeutics Co Total Stockholders Equity Chart

Qyuns Therapeutics Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Total Stockholders Equity
820.82 716.61 322.41 244.47

Qyuns Therapeutics Co Quarterly Data
Dec21 Dec22 Sep23 Dec23 Jun24 Dec24
Total Stockholders Equity Get a 7-Day Free Trial 716.61 425.57 322.41 395.75 244.47

Qyuns Therapeutics Co  (HKSE:02509) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Qyuns Therapeutics Co's Book Value per Share for the quarter that ended in Dec. 2024 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Qyuns Therapeutics Co's Debt-to-Equity for the quarter that ended in Dec. 2024 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qyuns Therapeutics Co Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Qyuns Therapeutics Co's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Qyuns Therapeutics Co Business Description

Traded in Other Exchanges
N/A
Address
No. 907 Yaocheng Avenue, Room 1310, Building 1, Taizhou, Jiangsu, CHN
Qyuns Therapeutics Co Ltd is a a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline.
Executives
Tai Zhou Yi Yao Cheng Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Tai Zhou Jian Xin Chuang Ye Tou Zi You Xian Gong Si 2101 Beneficial owner
Hang Zhou Zhong Mei Hua Dong Zhi Yao You Xian Gong Si 2101 Beneficial owner
Zhong Guo Yuan Da Ji Tuan You Xian Ze Ren Gong Si 2201 Interest of corporation controlled by you
Tai Zhou Yi Yao Gao Xin Ji Shu Chan Ye Tou Zi Fa Zhan You Xian Gong Si 2201 Interest of corporation controlled by you
Tai Zhou Yi Yao Gao Xin Qu Hua Yin Jin Rong Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Yuan Da Hua Chuang Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Hua Dong Yi Yao Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Qiu Jiwan
Xu Qiu
Hangzhou Quanyi Investment Management Partnership (general Partnership)
Yu Guo'an
Zhu Jing
Taizhou Xinfu Tongxin Enterprise Management Partnership (limited Partnership)
Sheng Xi Tai

Qyuns Therapeutics Co Headlines

No Headlines